Correction: Bispecific Nanobodies Targeting Bet v 1 and ICAM-1

Overview

This correction article updates the findings on bispecific nanobodies that target Bet v 1 and ICAM-1. A previously omitted reference has been added to support the discussion on Bet v 1's interaction with epithelial cells.

Background

Understanding the mechanisms of allergen penetration in respiratory epithelial cells is crucial for developing targeted therapies for allergic conditions. This correction emphasizes the importance of accurate citations in the ongoing research on allergen interactions with epithelial barriers.

Data Highlights

No numerical data or trial results were provided in the source material.

Key Findings

• The article includes a newly added reference discussing Bet v 1's penetration of respiratory epithelial cells.
• Transcytosis is recognized as a significant factor in Bet v 1 uptake.
• Recent findings indicate that Bet v 1 induces transcription of alarmins in airway epithelium.
• The correction highlights the importance of accurate reference citations in scientific literature.

Clinical Implications

The findings suggest that bispecific nanobodies could be a promising avenue for reducing allergen penetration in respiratory conditions. Clinicians should consider the evolving landscape of allergen-targeted therapies as research progresses.

Conclusion

This correction underscores the necessity of precise citations in scientific discourse.

Related Resources & Content

1. Zettl I et al., Front. Immunol, 2026 -- Correction: Bispecific Nanobodies Targeting Bet v 1 and ICAM-1 Reduce Penetration of Bet v 1 in Respiratory Epithelial Cells
2. retinal physician — Bispecific Antibodies in Retina Therapies
3. MDSpire News — New Bispecific Antibodies Neutralize SARS-CoV-2 Variants
4. Retinal Physician — Bispecific Antibodies in Retina Therapies
5. Frontiers in Immunology — DNase1 mitigates peribronchial inflammation in murine lung explants exposed to activated neutrophils
6. New Bispecific Antibodies Neutralize SARS-CoV-2 Variants
7. Bispecific Antibodies in Retina Therapies
8. Allergic Rhinitis and Its Impact on Asthma (ARIA)-EAACI Guidelines-2024-2025 Revision: Part I-Guidelines on Intranasal Treatments
9. Efficacy of allergen-specific immunotherapy for allergic rhinitis: a meta-analysis
10. Frontiers | The epithelial barrier: a Janus-faced regulator in allergic airway diseases from defense to inflammation